Through examination of traditional cytogenetic markers, gene mutations, exemplified as DNMT3A, MLL, NPM1, CEBPA, FLT3 mutations etc., and more importantly gene expression profile, especially for MECOM, MEIS1 and WT1, one could discriminate the AML patients with different clinical behaviors. The gene discussed is MECOM; the disease is acute myeloid leukemia.